Editorial

Double‐Blind Comparison of Hydrochlorothiazide Plus Triamterene Therapy Versus Chlorthalidone Therapy in Hypertension

Authors: EUGENE C. CLARK MD, STEPHEN PODOLSKY MD, EUGENE J. THOMPSON MD

Abstract

Effects of two dosage strengths of hydrochlorothiazide and triamterene in combination and chlorthalidone on blood pressure and serum potassium were compared in 126 patients in a double-blind, placebo-controlled study. Each drug regimen was administered once a day. All three regimens had significantly reduced blood pressure at each of the eight weeks of therapy. Compared to chlorthalidone, the lower dosage of hydrochlorothiazide/triamterene usually produced smaller decreases in blood pressure, while the higher dosage of the combination usually produced decreases of equal magnitude. The incidence of clinically significant hypokalemia, ie, serum potassium < 3.0 mEq/liter, was 0% for both dosage strengths of hydrochlorothiazide/triamterene and 15% for chlorthalidone. There were no significant differences among regimens in incidence of clinical adverse effects. These data indicate that the hydrochlorothiazide/triamterene combination can be used effectively on a once-a-day basis in the treatment of hypertension.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References